AccuMetab™ Human CYP2E1 Enzyme, Catalytically Active with Cytochrome b5

CAT#: ITS-0426-YL72
Product Type: Recombinant Phase I Metabolizing Enzyme
Brand: AccuMetab
Development Stage: ADME
ADME Research Domain: Metabolism
Short Description
Enhanced human CYP2E1 for high-activity Phase I metabolism profiling.
Brand
AccuMetab
Development Stage
ADME
ADME Research Domain
Metabolism
Background
Cytochrome b5 synergistically enhances CYP2E1 activity, promoting the rapid formation of reactive metabolic intermediates. This high-activity system is heavily favored by toxicologists conducting rigorous hepatotoxicity screening and reactive oxygen species (ROS) mapping.
Key Features
Cytochrome b5 supplemented for max catalytic turnover; Unmatched system for rapid ROS generation mapping; Premier in vitro model for acute hepatotoxicity; High-reductase expression for extreme specific activity
Applications
Enhanced Drug Metabolism Studies, MetID, DDI
Research Areas
ADME; Drug-Drug Interactions (DDI)
Species
Human
Expression System
Recombinant enzymes prepared from E. coli and co-expressed with NADPH CYP-reductase.
Physical Form
Liquid
Size
0.5 nmol; 1 nmol; 4 nmol; 10 mg
Storage
-80°C
Storage Comment
When stored at -80°C, our product remains stable and retains full functional activity for up to 10 years.
Note
For bulk pricing or custom reagent inquiries, please contact us by email or phone. Products are shipped on ice via FedEx.
Restrictions
For Research Use Only (RUO). Not intended for diagnostic or therapeutic use.
Shipping
Our enzyme products are shipped at -80°C.
For Research Use Only | Not For Clinical Use
Online Inquiry